Greenman, Cerus Corp president, sells $156k in CERS stock

CEO William Mariner Greenman sold 78,187 CERS shares at $2.0055 for $156,804 on March 6, 2026 to cover tax withholding and fees while also receiving 193,270 shares at no cost on March 5, leaving him with 5,446,250 shares. Cerus reported Q4 2025 revenue of $233.8M, up 16% YoY and above expectations, with EPS of -$0.01 in line with estimates; gross margin reported at 54%. The stock trades at $1.93 (down ~9% over the past week, up ~64% over six months) and InvestingPro flags it as potentially undervalued at current levels.

Analysis

The executive sale appears mechanical (RSU tax/brokerage) rather than a governance red flag, but the coincident vesting increased free float and likely amplified short-term volatility in an already thinly traded small cap. That dynamic explains recent intra-week weakness despite underlying margin strength; monitor whether selling persists on subsequent vesting cycles or if buyback/insider purchases resume as a signal of conviction.

Cerus’s gross-margin profile gives it optionality to leverage incremental revenue into free cash flow if SG&A growth is contained; the primary pathway to a re-rating is operational leverage from higher volumes (hospital adoption, recurring disposables) rather than one-off revenue beats. Key medium-term value drivers are contract scale and stickiness of consumable revenues — failure to convert top-line growth into positive EBIT/FCF within 12–18 months is the main downside runway.

Near-term catalysts (quarterly guidance, material new contracts, or regulatory clears) can produce asymmetric upside over 1–3 quarters; downside shocks include a pullback in elective procedure volumes, margin compression via competitive pricing, or dilution from equity-financing to fund growth. Also watch buyer concentration (GPO negotiations) — increased purchasing power among large health systems can compress ASPs and transfer margin to customers.

Second-order beneficiaries are suppliers of single-use consumables and contract manufacturers that scale with Cerus volumes; conversely, privately held competitors that can underprice to gain share represent a stealth risk. M&A interest from strategic acquirers would likely compress volatility and set a valuation floor; absence of interest keeps upside dependent on execution.

Key Decisions for Investors

• Buy CERS equity sized 2% NAV as a directional trade to capture conversion of revenue into margin over 6–12 months; set a tactical stop at -25% and a target of +60% to enforce discipline on binary operational outcomes.
• Buy a 9-month call spread (long lower strike / short higher strike to finance premium) sized 0.5–1% NAV to express asymmetric upside while limiting premium loss; target >3x return if the company prints follow-through revenue/EBIT beats, max loss = premium.
• Pair trade to remove market beta: long CERS (1.5% NAV) / short IBB (or a small-cap biotech ETF) (1.5% NAV) for 6–12 months to isolate company-specific execution risk while hedging sector/regulatory moves.
• If you already own shares, buy 6–9 month protective puts sized to cover 50% of position to limit tail risk from procedural-volume shocks or market-wide biotech drawdowns; cost can be offset by selling short-dated covered calls to harvest premium.